New drug combo aims to tackle diabetes and fatty liver together

This study is testing whether adding a third diabetes drug (alogliptin) to a standard two-drug combination (pioglitazone and metformin) works better for people who have both type 2 diabetes and fatty liver disease. Researchers will enroll 80 participants to see if the three-drug combo improves blood sugar control, cholesterol levels, and how well the pancreas works compared to the two-drug combo alone. The goal is to find a more effective way to manage these two common, linked conditions.